<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03622658</url>
  </required_header>
  <id_info>
    <org_study_id>IZN-101</org_study_id>
    <nct_id>NCT03622658</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis</brief_title>
  <acronym>NAMASTE</acronym>
  <official_title>A Phase 2a Proof of Concept, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety/Tolerability and Efficacy of 4 Subcutaneous Injections of Namilumab (150 mg) Given Over 10 Weeks in Subjects With Moderate-to-severely Active Axial Spondyloarthritis Including Those Previously Exposed to Anti-TNF Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Izana Bioscience Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innovate UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Izana Bioscience Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the effect of namilumab, a GM-CSF inhibitor, on the clinical response
      in subjects with axial spondyloarthritis. Subjects will receive treatment with either
      namilumab or placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2018</start_date>
  <completion_date type="Actual">February 4, 2020</completion_date>
  <primary_completion_date type="Actual">February 4, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of Namilumab</measure>
    <time_frame>Week 12</time_frame>
    <description>Number of subjects with 20% improvement in Assessment in Ankylosing Spondylitis Assessment (ASAS20) at the Week 12 visit.
clinical response at 12 weeks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo solution administered by subcutaneous injection on 4 occasions over 10 weeksx</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Namilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Namilumab (150 mg) administered by subcutaneous injection on 4 occasions over 10 weeksx</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo solution for subcutaneous injection.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Namilumab</intervention_name>
    <description>Namilumab solution for subcutaneous injection</description>
    <arm_group_label>Namilumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 and ≤ 75 years of age

          -  Diagnosis of axSpA by an appropriately qualified physician and classified using ASAS
             criteria ≥ 3 months prior to Baseline

          -  Bath Ankylosing Spondylitis Disease Activity Index score ≥ 4 and spinal pain score ≥
             40, at screening and Baseline.

          -  MRI evidence of active axSpA ≤ 6 (ideally ≤ 3) months prior to randomisation using
             ASAS criteria.

          -  Stable NSAID use prior to study entry

          -  Stable use of MTX, sulfasalazine orleflunomide to study entry

          -  Stable oral corticosteroid dose prior to study entry.

          -  Capable of giving signed informed consent

          -  Inadequately responded to or experienced intolerance to previous treatment with an
             anti-TNF agent (some subjects)

        Exclusion Criteria:

          -  Current diagnosis of axSpA with a BASDAI &gt; 4 but no evidence of inflammation on MRI

          -  Discontinued biologic therapy &lt; 8 weeks prior to Baseline.

          -  Previous or current use of oral corticosteroid as defined in protocol

          -  Received intra-articular or i.v. corticosteroids prior to or during Screening

          -  Received anti-IL-17A or anti IL12/23 therapy

          -  Received cyclosporine, tacrolimus or mycophenolate mofetil prior to Baseline

          -  Previously received stem cell transplantation

          -  Infection(s) requiring treatment with i.v. anti-infectives or oral anti-infectives
             prior to Baseline

          -  Abnormal screening laboratory and other analyses

          -  Receipt of any live vaccine within 2 weeks prior to randomisation, or will require
             live vaccination during study participation

          -  Evidence of current or prior dysplasia or history of malignancy

          -  Has had any uncontrolled and/or clinically significant illness, hospitalisation, or
             any surgical procedure requiring general anaesthesia prior to Screening, or any
             planned surgical procedure within 6 months after randomisation

          -  Known current or previous interstitial lung disease

          -  Positive pregnancy test at Screening (serum) or Baseline (urine)

          -  Female subjects who are breastfeeding or considering becoming pregnant during the
             study

          -  Considered by the Investigator to be an unsuitable candidate for the study

          -  Received any investigational agent or procedure within 30 days or 5 half-lives prior
             to Baseline

          -  Related to or a dependent of the site staff, or a member of the site staff
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Royal United Hospitals Bath</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingham</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Coventry and Warwickshire</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwick Park Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whipps Cross Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Berkshire Hospital</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haywood Hospital</name>
      <address>
        <city>Stoke-on-Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

